Print this page    •   Back to Web version of article

HIV Pipeline: Chart on Drugs in Development

Source: Ben Cheng, Project Inform4

Summer 2002

CompoundClass of CompoundPhase of DevelopmentPharmaceutical Company
ACH-126,443 (L-Fd4C)nucleoside analog RT inhibitorPhase 1Achilleon
ADAzinc fingerPhase 1-2Hubriphar
AMD-34653CXCR4 antagonistPreclinicalAnorMed
AMD-84453entry inhibitorPreclinicalAnorMed
Atazanavir (BMS-232623)protease inhibitorPhase 2-31Bristol-Myers Squibb
BCH-10618 (DOTC)nucleoside analog RT inhibitorPreclinicalShire Biochem
BEA-0053nucleoside analog RT inhibitorPreclinicalMedivir
Beta-D-Fd4C3nucleoside analog RT inhibitorPreclinicalVion
Beta-L-Fd4C3nucleoside analog RT inhibitorPreclinicalVion
BMS-806entry inhibitorPhase 1Bristol-Myers Squibb
Calanolide Anon-nucleoside RT inhibitorPhase 2Sarawak Medichem
Capravirinenon-nucleoside RT inhibitorPhase 2Pfizer/Agouron
DAPDnucleoside analog RT inhibitorPhase 1-2Triangle Pharmaceuticals
DEHSPMinhibits hypusin/eIF-5APhase 1SunPharm
DPC 083non-nucleoside RT inhibitorPhase 1-2DuPont Pharmaceuticals2
DPC 681protease inhibitorPreclinicalDupont Pharmaceuticals2
DPC 684protease inhibitorPreclinicalDupont Pharmaceuticals2
DPC 961non-nucleoside RT inhibitorPhase 1DuPont Pharmaceuticals2
Emivirine (MKC-442)non-nucleoside RT inhibitorPhase 3Triangle Pharmaceuticals
Emtricitabine (FTC)nucleoside analog RT inhibitorPhase 3Triangle Pharmaceuticals
HI-2363non-nucleoside RT inhibitorPreclinicalWayne Hughes Institute
Hu5A83binding inhibitorPreclinicalTanox
Hydroxyureainhibits cellular factorsPhase 2-3Bristol-Myers Squibb
L-870,810integrase inhibitorPhase 1Merck & Co.
LB-713503protease inhibitorPreclinicalLG Chemical
Mycophenlateinhibits cellular factorsPhase 1-2Hoffman-La Roche
Peldesineinhibits cellular factorsPhase 1Biocryst
Pentfuside (T-20)fusion inhibitorPhase 31Trimeris/Roche
Phosphazid3nucleoside analog RT inhibitorPreclinicalViscount
PNU142721non-nucleoside RT inhibitorPreclinicalPharmacia
PRO 140CCR5 antagonistPreclinicalProgenics
PRO 367entry inhibitorPhase 1Progenics
PRO 542attachment inhibitorPhase 1-2Progenics
RD4-22173non-nucleoside RT inhibitorPreclinicalTosoh
Resveratrolinhibits cellular factorsPhase 1Pharmascience
S-1360integrase inhibitorPhase 1-2Shionogi Pharmaceuticals
SCH CCCR5 antagonistPhase 1Schering Plough
SCH DCCR5 antagonistPreclinicalSchering Plough
SJ-33663non-nucleoside RT inhibitorPreclinicalSamjin
T-1249fusion inhibitorPhase 1Trimeris/Roche
TAK 449CCR5 antagonistPreclinicalTakeda
Tipranavirprotease inhibitorPhase 1-2Boehringer Ingelheim
TMC 125non-nucleoside RT inhibitorPhase 2Tibotec Virco
TMC 120non-nucleoside RT inhibitorPhase 2Tibotec Virco
TMC 126protease inhibitorPhase 1Tibotec Virco
UC-7813non-nucleoside RT inhibitorPreclinicalUniroyal
UK-427,857CCR5 antagonistPreclinicalPfizer
VX-175/GW433908 (amprenavir prodrug)protease inhibitorPhase 2-3Vertex/GlaxoSmithKline


Note: RT stands for Reverse Transcriptase

  1. Available in expanded access

  2. Dupont Pharmaceuticals sold its anti-HIV drug Sustiva and its HIV research pipeline to Bristol-Myers Squibb in 2001

  3. No information available

  4. Ben Cheng is now the Project Manager at the Forum for Collaborative HIV Research in Washington, DC (www.hivforum.org).


Back to the RITA! Summer 2002 contents page.




This article was provided by The Center for AIDS. It is a part of the publication Research Initiative/Treatment Action!. You can find this article online by typing this address into your Web browser:
http://www.thebody.com/content/art16848.html

General Disclaimer: TheBody.com is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through TheBody.com should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.